TY - JOUR
T1 - Clinical outcomes of women with recurrent or persistent uterine leiomyosarcoma
AU - Rauh-Hain, Jose Alejandro
AU - Hinchcliff, Emily M.
AU - Oduyebo, Titilope
AU - Worley, Michael J.
AU - Andrade, Carolina A.
AU - Schorge, John O.
AU - George, Suzanne
AU - Muto, Micheal G.
AU - Del Carmen, Marcela G.
N1 - Publisher Copyright:
Copyright © 2014 by oIGCS and ESGO.
PY - 2014/1/1
Y1 - 2014/1/1
N2 - Objectives: This study aimed to identify prognostic factors influencing the outcome of recurrent or persistent uterine leiomyosarcoma (ULMS). Methods: All patients with recurrent or persistent ULMS who underwent treatment at the participating institutions between January 2000 and December 2010 were identified from the tumor registry. The Kaplan-Meier method was used to generate overall survival data. Factors predictive of outcome were compared using the log-rank test and Cox proportional hazards model. Results: One hundred fifteen (68.8%) patients who had recurrent/persistent disease were identified, 40 (34.8%) had persistent disease, and 75 (65.2%) had a recurrence. Median follow-up time was 24.9 months. The 5-year postrelapse survival rate was 15% and was not significantly different between women with recurrent or persistent disease (16% vs 13%; P = 0.1). Variables identified affecting the 5-year postrelapse survival rate included low number of mitosis at the time of diagnosis (<25, 25%vs 5%; P = 0.002), time to relapse from original diagnosis (≤6 vs >6 months, 8% vs 22%; P = 0.003)), and surgical treatment (17% vs 12%; P = 0.01). Age, stage, chemotherapy at time of original diagnosis or at the time of relapse, site of recurrence, and single versus multiple sites of recurrence were not associated with survival. In a multivariate Cox regression model, only low number of mitosis (hazard ratio, 0.5; 95% confidence interval, 0.3-0.8, P = 0.02) was identified as a predictor of overall survival. Conclusions: The prognosis of patients with recurrent/persistent ULMS is, in general, poor. Women who have low number of mitosis at the time of diagnosis seemed to have better postrelapse survival.
AB - Objectives: This study aimed to identify prognostic factors influencing the outcome of recurrent or persistent uterine leiomyosarcoma (ULMS). Methods: All patients with recurrent or persistent ULMS who underwent treatment at the participating institutions between January 2000 and December 2010 were identified from the tumor registry. The Kaplan-Meier method was used to generate overall survival data. Factors predictive of outcome were compared using the log-rank test and Cox proportional hazards model. Results: One hundred fifteen (68.8%) patients who had recurrent/persistent disease were identified, 40 (34.8%) had persistent disease, and 75 (65.2%) had a recurrence. Median follow-up time was 24.9 months. The 5-year postrelapse survival rate was 15% and was not significantly different between women with recurrent or persistent disease (16% vs 13%; P = 0.1). Variables identified affecting the 5-year postrelapse survival rate included low number of mitosis at the time of diagnosis (<25, 25%vs 5%; P = 0.002), time to relapse from original diagnosis (≤6 vs >6 months, 8% vs 22%; P = 0.003)), and surgical treatment (17% vs 12%; P = 0.01). Age, stage, chemotherapy at time of original diagnosis or at the time of relapse, site of recurrence, and single versus multiple sites of recurrence were not associated with survival. In a multivariate Cox regression model, only low number of mitosis (hazard ratio, 0.5; 95% confidence interval, 0.3-0.8, P = 0.02) was identified as a predictor of overall survival. Conclusions: The prognosis of patients with recurrent/persistent ULMS is, in general, poor. Women who have low number of mitosis at the time of diagnosis seemed to have better postrelapse survival.
KW - Uterine cancer
KW - Uterine leiomyosarcoma
UR - http://www.scopus.com/inward/record.url?scp=84925647277&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84925647277&partnerID=8YFLogxK
U2 - 10.1097/IGC.0000000000000221
DO - 10.1097/IGC.0000000000000221
M3 - Article
C2 - 25248114
AN - SCOPUS:84925647277
SN - 1048-891X
VL - 24
SP - 1434
EP - 1440
JO - International Journal of Gynecological Cancer
JF - International Journal of Gynecological Cancer
IS - 8
ER -